Начало › Рак на яйчниците › Мичиган › Detroit
Клинични проучвания за Рак на яйчниците в Detroit, MI
26 проучвания за Рак на яйчниците търсят участници в обекти в и около Detroit (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
The Vanguard Study: Testing a New Way to Screen for Cancer
Набиране на участнициЗдравите доброволци са добре дошли
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Набиране на участнициФаза 2/3
- Henry Ford Hospital, Detroit
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Набиране на участнициФаза 1/2
- Research Site, Detroit
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Набиране на участнициНаблюдателно проучване
- Henry Ford Health, Detroit
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Набиране на участнициФаза 1/2
- Karmanos Cancer Institute, Detroit
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Набиране на участнициФаза 2
- Site 0101 - Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Набиране на участнициФаза 1/2
- Karmanos Cancer Institute, Detroit
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Набиране на участнициФаза 3
- Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Набиране на участнициФаза 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Набиране на участнициФаза 2
- Karmanos Cancer Institute - Detroit /ID# 277085, Detroit
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Набиране на участнициФаза 3
- Henry Ford Cancer - Detroit, Detroit
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Набиране на участнициФаза 2
- Karmanos Cancer Institute, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Набиране на участнициФаза 1
- Karmanos Cancer Institiute, Detroit
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Набиране на участнициФаза 3
- Karmanos Cancer Institute, Detroit
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Набиране на участнициФаза 1
- Karmanos Cancer Institute, Detroit
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Набиране на участнициФаза 1
- Karmanos Cancer Center, Detroit
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Набиране на участнициФаза 3
- Henry Ford Health Saint John Hospital, Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Набиране на участнициФаза 1/2
- Karmanos Cancer Institute, Detroit
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Набиране на участнициФаза 1
- Karmanos Cancer Institute, Detroit
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Набиране на участнициФаза 1/2
- Henry Ford Health Hospital, Detroit
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Набиране на участнициФаза 2
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Набиране на участнициФаза 2
- Karmanos Cancer Institute - Detroit /ID# 272112, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Набиране на участнициФаза 1/2
- Karmanos Cancer Institute, Detroit
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Набиране на участнициФаза 1
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
Набиране на участнициФаза 1/2
- Karmanos Cancer Institute, Detroit
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Набиране на участнициФаза 1
- Karmanos Cancer Institute, Detroit
Проучвания за Рак на яйчниците в други градове
- Houston, TX89 проучвания
- New York City, NY69 проучвания
- Boston, MA61 проучвания
- Los Angeles, CA50 проучвания
- Nashville, TN49 проучвания
- Arlington, VA46 проучвания
- Philadelphia, PA44 проучвания
- Columbus, OH39 проучвания
- St. Louis, MO38 проучвания
- Chicago, IL36 проучвания
- San Antonio, TX31 проучвания
- Cleveland, OH30 проучвания
Други проучвания в Detroit
- Рак на белия дроб с недребноклетъчен тип44 проучвания
- Рак на гърдата33 проучвания
- Рак (всички видове)29 проучвания
- Колоректален рак26 проучвания
- Метастатичен рак24 проучвания
- Рак на простатата22 проучвания
- Ендометриален рак21 проучвания
- Рак на белия дроб20 проучвания
- Множествен миелом19 проучвания
- Рак на стомаха16 проучвания
- Плоскоклетъчен карцином на главата и шията15 проучвания
- Остра миелоидна левкемия14 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.